Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

**25 November 2026**

ASX Market Announcements
ASX Limited
Level 4
Stock Exchange Centre
20 Bridge Street
SYDNEY NSW 2000

Dear Sir/Madam

**RESULTS OF ANNUAL GENERAL MEETING**

In accordance with Listing Rule 3.13.2 and Section 251AA of the *Corporations Act 2001* (Cth), we advise details of the resolutions and the proxies received in respect of each resolution as set out in the attached proxy summary.

Yours sincerely,
**NEURIZON THERAPEUTICS LIMITED**

Stefan Ross
Company Secretary

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

**Marketing & Corporate Affairs**
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

**Investor Relations**
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

## About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

## Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited

Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

# Neurizon Therapeutics Limited
# Annual General Meeting
# Wednesday, 25 November 2026
# Voting Results

The following information is provided in accordance with section 251AA(2) of *Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2*:

| Resolution Details | | | | Show of Hands (S) or Poll (P) | Instructions given to validly appointed proxies (as at proxy close) | | | | Number of votes cast on the poll (where applicable) | | | Res. Results |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resolution | | Resolution Type | If s250U applies | S or P | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried /Not Carried |
| 1. | Adoption of Remuneration Report | Ordinary | N/A | P | 303,688,883<br>79.88% | 75,916,410<br>19.97% | 566,518<br>0.15% | 1,219,306<br>- | 314,132,691<br>80.19% | 77,616,410<br>19.81% | 1,219,306<br>- | Carried |
| 2. | Election of Dr Ross Murdoch as a Director of the Company | Ordinary | N/A | P | 382,406,083<br>93.38% | 26,525,538<br>6.48% | 586,518<br>0.14% | 2,603,789<br>- | 394,572,349<br>93.58% | 27,064,708<br>6.42% | 2,603,789<br>- | Carried |
| 3. | Grant of Options to Dr Ross Murdoch - NED Offer | Ordinary | N/A | P | 347,982,942<br>92.52% | 27,127,348<br>7.21% | 989,441<br>0.26% | 8,745,773<br>- | 361,091,301<br>93.57% | 24,827,348<br>6.43% | 11,045,773<br>- | Carried |
| 4. | Approval to issue Convertible Notes to Obsidian Global GP, LLC (and/or its nominee(s)) | Ordinary | N/A | N/A | This resolution was withdrawn prior to the meeting as announced | | | | | | | N/A |
| 5. | Approval of 10% Placement Facility | Special | N/A | P | 342,464,316<br>84.16% | 63,877,442<br>15.70% | 566,518<br>0.14% | 5,213,652<br>- | 348,653,932<br>83.21% | 70,373,262<br>16.79% | 5,213,652<br>- | Carried |

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.